Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Viridian Therapeutics, Inc.\DE
| Metric | Viridian Therapeutics, Inc.\DE VRDNHealthcare |
|---|---|
| Quality Score | 67 / 100 |
| Revenue (latest) | $71M |
| Net income (latest) | −$343M |
| Operating margin | −512.9% |
| Net margin | −483.6% |
| Return on equity | −47.4% |
| Return on assets | −38.1% |
| Return on capital (ROCE) | −43.9% |
| Debt / equity | 0.25× |
| Revenue growth (YoY) | 23359.9% |
| Altman Z″ (distress) | 2.72 |
| Accruals / assets | −7.4% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.